Larimar Therapeutics Inc. (NASDAQ: LRMR)
$10.00
-0.5850 ( -5.53% ) 178.2K
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
Market Data
Open
$10.00
Previous close
$10.58
Volume
178.2K
Market cap
$636.74M
Day range
$9.88 - $10.57
52 week range
$2.18 - $13.68
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Oct 05, 2023 |
3 | Insider transactions | 2 | Oct 05, 2023 |
8-k | 8K-related | 12 | Oct 03, 2023 |
8-k | 8K-related | 57 | Aug 14, 2023 |
10-q | Quarterly Reports | 54 | Aug 10, 2023 |
8-k | 8K-related | 14 | Aug 10, 2023 |
8-k | 8K-related | 27 | Jul 25, 2023 |
3 | Insider transactions | 2 | Jul 18, 2023 |
4 | Insider transactions | 1 | Jul 18, 2023 |
8-k | 8K-related | 14 | Jul 17, 2023 |